CASI Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CASI Pharmaceuticals, Inc.
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.
As hospital drug shortages continue to bite in the US, a group purchasing organization has invested in generic injectables specialist Exela Pharma Sciences to garner uninterrupted supply of 19 pharmaceutical products.
Mead Johnson pulls challenged claims before National Advertising Division began a review in its SWIFT process, but not before Nestlé Nutrition, which markets Gerber infant formula, submitted its challenge.
- Other Names / Subsidiaries
- EntreMed, Inc.
- Miikana Therapeutics, Inc.